All Stories

  1. MicroRNAs as biomarkers in malignant pleural mesothelioma

    Article • Current Biomarker Findings, December 2015, Dove Medical Press

    Dr Eric Santoni-Rugiu, Dr Morten Andersen

  2. Use of TUBB3 for patient stratification and prognosis in lung cancer

    Article • Lung Cancer Management, April 2015, Future Medicine

    Dr Eric Santoni-Rugiu

  3. Molecular imaging in Libman-Sacks endocarditis

    Article • Infectious Diseases, January 2015, Taylor & Francis

    Dr Eric Santoni-Rugiu

  4. Personalized oncology: genomic screening in phase 1

    Article • Apmis, July 2014, Wiley

    Dr Eric Santoni-Rugiu

  5. Diagnostic Potential of miR-126, miR-143, miR-145, and miR-652 in Malignant Pleural Mesothelioma

    Article • Journal of Molecular Diagnostics, July 2014, Elsevier

    Dr Eric Santoni-Rugiu

  6. Thymidylate synthase protein expression levels remain stable during paclitaxel and carboplatin treatment in non-small cell lung cancer

    Article • Journal of Cancer Research and Clinical Oncology, February 2014, Springer Science + Business Media

    Dr Eric Santoni-Rugiu

  7. Changes in epidermal growth factor receptor expression during chemotherapy in non-small cell lung cancer

    Article • Cancer Chemotherapy and Pharmacology, December 2013, Springer Science + Business Media

    Dr Eric Santoni-Rugiu

  8. Differences in RRM1 protein expression between diagnostic biopsies and resection specimens, and changes during carboplatin and paclitaxel treatment, in non-small-cell lung cancer

    Article • Histopathology, November 2013, Wiley

    Dr Eric Santoni-Rugiu

  9. Longitudinal assessment of TUBB3 expression in non-small cell lung cancer patients

    Article • Cancer Chemotherapy and Pharmacology, November 2013, Springer Science + Business Media

    Dr Eric Santoni-Rugiu

  10. Loss of miR-10a Activates Lpo and Collaborates with Activated Wnt Signaling in Inducing Intestinal Neoplasia in Female Mice

    Article • PLoS Genetics, October 2013, PLOS

    Professor Anders H Lund, Dr Eric Santoni-Rugiu

  11. Prdm5 suppresses ApcMin-driven intestinal adenomas and regulates monoacylglycerol lipase expression

    Article • Oncogene, July 2013, Nature

    Dr Eric Santoni-Rugiu

  12. Intratumour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer

    Article • European Journal of Cancer, July 2013, Elsevier

    Dr Eric Santoni-Rugiu

  13. Abstract 3556: Diagnostic potential of microRNAs (miRs) in malignant pleural mesothelioma (MPM).

    Article • Cancer Research, April 2013, American Association for Cancer Research (AACR)

    Dr Eric Santoni-Rugiu

  14. Ly6/uPAR-Related Protein C4.4A as a Marker of Solid Growth Pattern and Poor Prognosis in Lung Adenocarcinoma

    Article • Journal of Thoracic Oncology, February 2013, Elsevier

    Dr Eric Santoni-Rugiu

  15. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotin...

    Article • BMC Research Notes, January 2013, Springer Science + Business Media

    Dr Eric Santoni-Rugiu

  16. 83 HDAC expression levels may play a role in cisplatin resistant MPM

    Article • Lung Cancer, January 2013, Elsevier

    Dr Eric Santoni-Rugiu

  17. Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial

    Article • Annals of Oncology, October 2012, Oxford University Press (OUP)

    Dr Eric Santoni-Rugiu

  18. A biomarker profile for predicting efficacy of cisplatin–vinorelbine therapy in malignant pleural mesothelioma

    Article • Cancer Chemotherapy and Pharmacology, September 2012, Springer Science + Business Media

    Dr Eric Santoni-Rugiu

  19. No Effect of NGAL/lipocalin-2 on Aggressiveness of Cancer in the MMTV-PyMT/FVB/N Mouse Model for Breast Cancer

    Article • PLoS ONE, June 2012, PLOS

    Dr Eric Santoni-Rugiu

  20. The diagnostic value of immunohistochemically detected methylthioadenosine phosphorylase deficiency in malignant pleural mesotheliomas

    Article • Histopathology, March 2012, Wiley

    Dr Eric Santoni-Rugiu

  21. Are differentially expressed microRNAs useful in the diagnostics of malignant pleural mesothelioma?

    Article • Apmis, March 2012, Wiley

    Dr Eric Santoni-Rugiu

  22. RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC

    Article • Lung Cancer, March 2012, Elsevier

    Dr Eric Santoni-Rugiu

  23. Low ERCC1 Expression in Malignant Pleural Mesotheliomas Treated with Cisplatin and Vinorelbine Predicts Prolonged Progression-Free Survival

    Article • Journal of Thoracic Oncology, January 2012, Elsevier

    Dr Eric Santoni-Rugiu

  24. PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab

    Article • Annals of Oncology, December 2011, Oxford University Press (OUP)

    Dr Eric Santoni-Rugiu

  25. Urokinase plasminogen activator receptor on invasive cancer cells: A prognostic factor in distal gastric adenocarcinoma

    Article • International Journal of Cancer, October 2011, Wiley

    Dr Martin Illemann, Dr Eric Santoni-Rugiu

  26. PP 88 C4.4A as a biomarker for poor prognosis in non-small cell lung cancer patients with adenocarcinomas

    Article • European Journal of Cancer, October 2011, Elsevier

    Dr Eric Santoni-Rugiu

  27. Expression of C4.4A in precursor lesions of pulmonary adenocarcinoma and squamous cell carcinoma

    Article • International Journal of Cancer, August 2011, Wiley

    Dr Martin Illemann, Dr Eric Santoni-Rugiu

  28. Class III  -Tubulin in Advanced NSCLC of Adenocarcinoma Subtype Predicts Superior Outcome in a Randomized Trial

    Article • Clinical Cancer Research, June 2011, American Association for Cancer Research (AACR)

    Dr Eric Santoni-Rugiu

  29. MMSET Is Highly Expressed and Associated with Aggressiveness in Neuroblastoma

    Article • Cancer Research, April 2011, American Association for Cancer Research (AACR)

    Dr Eric Santoni-Rugiu

  30. The Histone Methyltransferase and Putative Oncoprotein MMSET Is Overexpressed in a Large Variety of Human Tumors

    Article • Clinical Cancer Research, March 2011, American Association for Cancer Research (AACR)

    Dr Eric Santoni-Rugiu

  31. The level of claudin-7 is reduced as an early event in colorectal carcinogenesis

    Article • BMC Cancer, January 2011, Springer Science + Business Media

    Dr Eric Santoni-Rugiu

  32. Safety Pharmacology, Toxicology and Pharmacokinetic Assessment of Human Gc Globulin (Vitamin D Binding Protein)

    Article • Basic & Clinical Pharmacology & Toxicology, June 2010, Wiley

    Dr Eric Santoni-Rugiu

  33. ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial

    Article • European Journal of Cancer, June 2010, Elsevier

    Dr Eric Santoni-Rugiu

  34. Ossifying thymoma associated with refractory myasthenia gravis

    Article • Apmis, April 2010, Wiley

    Dr Eric Santoni-Rugiu

  35. ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial

    Article • Annals of Oncology, March 2010, Oxford University Press (OUP)

    Dr Eric Santoni-Rugiu

  36. Lipocalin 2 is protective against E. coli pneumonia

    Article • BMJ Open Respiratory Research, January 2010, Springer Science + Business Media

    Dr Eric Santoni-Rugiu

  37. Magnetic resonance imaging with liver-specific contrast agent in primary amyloidosis and intrahepatic cholestasis

    Article • Acta Radiologica, March 2007, SAGE Publications

    Dr Eric Santoni-Rugiu

  38. Remarkable heterogeneity displayed by oval cells in rat and mouse models of stem cell–mediated liver regeneration

    Article • Hepatology, January 2007, Wiley

    Dr Eric Santoni-Rugiu

  39. Progenitor cells in liver regeneration: molecular responses controlling their activation and expansion

    Article • Apmis, November 2005, Wiley

    Dr Eric Santoni-Rugiu

  40. Conditional E2F1 activation in transgenic mice causes testicular atrophy and dysplasia mimicking human CIS

    Article • Oncogene, November 2004, Nature

    Dr Eric Santoni-Rugiu

  41. Cancer predisposition in mice deficient for the metastasis-associated Mts1(S100A4) gene

    Article • Oncogene, April 2004, Nature

    Dr Eric Santoni-Rugiu

  42. Transit-Amplifying Ductular (Oval) Cells and Their Hepatocytic Progeny Are Characterized by a Novel and Distinctive Expression of Delta-Like Protein/Preadipocyte Factor 1/Fetal Antigen 1

    Article • American Journal Of Pathology, April 2004, Elsevier

    Dr Eric Santoni-Rugiu

  43. Heterogeneity of Ductular Reactions in Adult Rat and Human Liver Revealed by Novel Expression of Deleted in Malignant Brain Tumor 1

    Article • American Journal Of Pathology, October 2002, Elsevier

    Dr Eric Santoni-Rugiu

  44. E2F activity is essential for survival of Myc-overexpressing human cancer cells

    Article • Oncogene, September 2002, Nature

    Dr Eric Santoni-Rugiu

  45. Involvement of Myc Activity in a G1/S-Promoting Mechanism Parallel to the pRb/E2F Pathway

    Article • Molecular and Cellular Biology, May 2000, ASM Journals

    Dr Eric Santoni-Rugiu

  46. p16INK4a, but not constitutively active pRb, can impose a sustained G1 arrest: molecular mechanisms and implications for oncogenesis

    Article • Oncogene, July 1999, Nature

    Dr Eric Santoni-Rugiu

  47. Acceleration of c-myc-Induced Hepatocarcinogenesis by Co-Expression of Transforming Growth Factor (TGF)-α in Transgenic Mice Is Associated with TGF-β1 Signaling Disruption

    Article • American Journal Of Pathology, June 1999, Elsevier

    Dr Eric Santoni-Rugiu

  48. Transgenic animals as models for hepatocarcinogenesis

    Article • January 1998, Springer Science + Business Media

    Dr Eric Santoni-Rugiu

  49. Functional characterization of the rat mdr1b encoded P-glycoprotein: not all inducing agents are substrates

    Article • Carcinogenesis, November 1997, Oxford University Press (OUP)

    Dr Eric Santoni-Rugiu

  50. Growth Inhibition and Induction of Apoptosis by HGF in Transformed Rat Liver Epithelial Cells

    Article • Biochemical and Biophysical Research Communications, July 1997, Elsevier

    Dr Eric Santoni-Rugiu

  51. Interaction of c-myc with transforming growth factor α and hepatocyte growth factor in hepatocarcinogenesis

    Article • Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, May 1997, Elsevier

    Dr Eric Santoni-Rugiu

  52. Hepatic Tumor Induction in c- Myc mono-transgenic and TGF- α/c-Myc double-transgenic Mice

    Article • January 1997, Springer Science + Business Media

    Dr Eric Santoni-Rugiu

  53. Transgenic mouse models in carcinogenesis: Interaction of c-myc with transforming growth factor α and hepatocyte growth factor in hepato-carcinogenesis

    Article • Toxicology Letters, October 1996, Elsevier

    Dr Eric Santoni-Rugiu

  54. Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model.

    Article • Proceedings of the National Academy of Sciences, September 1996, Proceedings of the National Academy of Sciences

    Dr Eric Santoni-Rugiu

  55. Transgenic mouse models in carcinogenesis: interaction of c-myc with transforming growth factor α and hepatocyte growth factor in hepatocarcinogenesis

    Article • British Journal of Clinical Pharmacology, July 1996, Wiley

    Dr Eric Santoni-Rugiu

  56. Proliferation, apoptosis, and induction of hepatic transcription factors are characteristics of the early response of biliary epithelial (oval) cells to chemical carcinogens

    Article • Hepatology, January 1996, Wiley

    Dr Eric Santoni-Rugiu

  57. In vivo infusion of growth factors enhances the mitogenic response of rat hepatic ductal (oval) cells after administration of 2-acetylaminofluorene

    Article • Hepatology, January 1996, Wiley

    Dr Eric Santoni-Rugiu

  58. Differential modulation of P-glycoprotein expression by dexamethasone and 3-methycholanthrene in rat hepatocyte primary cultures

    Article • Carcinogenesis, January 1994, Oxford University Press (OUP)

    Dr Eric Santoni-Rugiu

  59. Inducibility of gamma-glutamyltransferase by dexamethasone in rat liver: Relationship with the cytochrome P-450 content

    Article • Life Sciences, January 1993, Elsevier

    Dr Eric Santoni-Rugiu

  60. Assessment of P-glycoprotein-dependent drug transport in isolated rat hepatocytes using rhodamine 123

    Article • Cell Biology and Toxicology, January 1993, Springer Science + Business Media

    Dr Eric Santoni-Rugiu

  61. Use of rhodamine 123 to assess P-glycoprotein activity in cultured rat hepatocytes

    Article • European Journal of Cancer and Clinical Oncology, January 1991, Elsevier

    Dr Eric Santoni-Rugiu